Coronavirus Update: Moderna Still Confident Of November Readout

Neck And Neck With Pfizer

30 Oct 2020

• By Scrip Team

The company said its own calculations suggested a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.

Paris 16 10 2020 Europe Under Lockdown — Paris, France: President Macron has imposed a new lockdown on the country, to last until at least the end of November. Like much of Europe, France is experiencing rapidly rising infection rates.

Moderna is confident that its COVID-19 vaccine candidate mRNA-1273 is on track to report early data by mid-November, which could set up an emergency use authorization if the data are encouraging.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

17 Feb 2025

• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

20 Jan 2025

• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

Stock Watch: Q3, Bonfire Of The Vaccine Manufacturers

13 Nov 2024

• By Andy Smith

Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.

Meiji Considers Legal Action Amid Japan Misinformation On Kostaive Vaccine

17 Oct 2024

• By Lisa Takagi

Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.